{"organizations": [], "uuid": "128a42e5563ef5eed12efc6b8ff58874b231cc7e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180214.html", "section_title": "Archive News &amp; Video for Wednesday, 14 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-intercept-pharmaceuticals-reports/brief-intercept-pharmaceuticals-reports-q4-net-loss-per-common-potential-common-share-4-43-idUSL8N1Q44TD", "country": "US", "domain_rank": 408, "title": "BRIEF-Intercept Pharmaceuticals Reports Q4 Net Loss Per Common & Potential Common Share $4.43", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.782, "site_type": "news", "published": "2018-02-14T20:26:00.000+02:00", "replies_count": 0, "uuid": "128a42e5563ef5eed12efc6b8ff58874b231cc7e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-intercept-pharmaceuticals-reports/brief-intercept-pharmaceuticals-reports-q4-net-loss-per-common-potential-common-share-4-43-idUSL8N1Q44TD", "ord_in_thread": 0, "title": "BRIEF-Intercept Pharmaceuticals Reports Q4 Net Loss Per Common & Potential Common Share $4.43", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters) - intercept pharmaceuticals inc", "sentiment": "neutral"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 14 (Reuters) - Intercept Pharmaceuticals Inc:\n* INTERCEPT PHARMACEUTICALS REPORTS FULL YEAR AND FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE\n* REGENERATE TRIAL IN NASH FIBROSIS ON TRACK TO REPORT DATA IN 1H19\n* PROJECTS NON-GAAP ADJUSTED OPERATING EXPENSES OF $390 MILLION TO $410 MILLION FOR FISCAL YEAR ENDING DEC 31, 2018\n* QTRLY NET LOSS PER COMMON AND POTENTIAL COMMON SHARE $4.43\n* Q4 EARNINGS PER SHARE VIEW $-3.55, REVENUE VIEW $39.0 MILLION -- THOMSON REUTERS I/B/E/S\n* Q4 REVENUE $37.7 MILLION Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-14T20:26:00.000+02:00", "crawled": "2018-02-15T20:54:28.019+02:00", "highlightTitle": ""}